Clinical Trials Directory

Trials / Unknown

UnknownNCT04871802

Effect of the Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID-19 Pneumonia

A Prospective, Randomized, Comparative Study in Two Groups to Assess the Effect of the Use of a Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID Pneumonia and on the Biological Age

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Pirogov Russian National Research Medical University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Objective of the study is to evaluate the effect of Taxifolin Aqua therapy on the indicators of respiratory function, the state of the arterial wall, the contractile function of the myocardium, as well as to assess the effect of Taxifolin Aqua therapy on markers of biological age, quality of patients life.

Detailed description

The study will include 100 patients who had covid pneumonia 3 months ago. If the inclusion / exclusion criteria are met, the patient is asked to sign an informed consent to participate in the study. Consenting patients are randomized to an intervention group or a control group. The control group (n = 50) will receive standard therapy, patients from the intervention group (n = 50) will be prescribed Taxifolin Aqua 30 mg per day in addition to standard therapy. Patients will be randomized to the control and main group using random number spreadsheets, assuming that the control and main groups will be homogeneous in the main demographic and clinical parameters. Patient monitoring will be carried out within 2 months from the date of inclusion. A follow-up visit is scheduled in 2 months. During the study, the patient will be regularly monitored for tolerance and safety of therapy with Taxifolin Aqua.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTTaxifolin AquaDietary supplement

Timeline

Start date
2021-05-10
Primary completion
2021-09-01
Completion
2021-10-01
First posted
2021-05-04
Last updated
2021-05-04

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT04871802. Inclusion in this directory is not an endorsement.